A retrospective study found that the use of GLP1R agonists was associated with lower risk for 10 of the 13 obesity-associated cancers in type 2 diabetes patients although the mechanisms remain unclear, suggesting a need for further preclinical and clinical investigation17. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.